MENTAL HEALTH 5 HTIA RECEPTOR AND NEUROPLASTICITY

心理健康 5 HTIA 受体和神经可塑性

• 批准号: 6888128
• 负责人: Efrain C Azmitia
• 金额: $ 12.1万
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6888128
• 关键词: apoptosis; bioimaging /biomedical imaging; clinical research; developmental neurobiology; human subject; longitudinal human study; magnetic resonance imaging; neural plasticity; neurogenesis; neuroimaging; receptor expression; serotonin inhibitor; serotonin receptor

DESCRIPTION: This is a request for an NIMH Senior Scientist Award (SSA). At the age of 52, with over 30 years of research experience, I request freedom from non-research duties in order to focus on an expanded research program and take advantage of a unique and timely opportunity to learn MRI in humans. The major aim of my present research program is to examine the basic cellular and pharmacological mechanism of serotonin-mediated neuroplasticity in the rodent brain and spinal cord. The research proposed for the next five years focuses my efforts on expanding my basic research objectives and extending them to include clinical research. In basic research, I will study the serotonin involvement with neurogenesis and apoptosis. My current hypothesis is that 5-HT1A receptor protein levels and expression are inversely correlated with neuronal maturation. Dr. Jacobs finds neurogenesis is stimulated by 5-HT1A receptor agonists. Dr. Banerjee reports 5-HT1A agonists activate MAP-kinase, which inhibits caspase-3 activity and apoptosis, in a neuronal cell line. I am positioned to move into these areas and expand on my current NIMH supported research that linked the 5-HT1A receptor to neuroplasticity and depression. I will expand my hypothesis to include events occurring during neurogenesis and apoptosis. The second major career plan involves acquiring the background and experience to perform and analyse MRI in the human brain. Dr. Mony DeLeon uses MRI to detect morphological changes in entorhinal cortex, amygdala and hippocampus at NYU Medical Center. My long-term aims are to use imaging techniques for longitudinal study of a psychiatric patient population where neuroplastic events are suspected. Therapeutic strategies using 5-HT drugs would enable direct testing of the clinical relevance of my basic research findings. Professional growth plans involve (a) supplemental training in human imaging technology; (b) explore the role of the 5-HT1A receptor in neurogenesis and apoptosis and (c) meet with national and international experts in the field of neuroplasticity as part of further development of therapeutic strategies for using pharmacology to reverse neuromorphological changes occurring in mental disorders.

描述：这是对NIMH高级科学家奖（SSA）的请求。在 我52岁，有30多年的研究经验，我要求自由， 非研究职责，以专注于扩大研究计划，并采取 这是一个独特而及时的机会来学习人类MRI。主要 我目前的研究计划的目的是检查基本的细胞和 啮齿类动物神经可塑性的药理学机制 大脑和脊髓。未来五年的研究重点是 努力扩大我的基础研究目标，并将其扩展到包括 临床研究在基础研究中，我将研究血清素参与 与神经发生和细胞凋亡有关。我目前的假设是5-HT 1A受体 蛋白质水平和表达与神经元 成熟Jacobs博士发现神经发生受5-HT 1A受体刺激 激动剂Banerjee博士报告说，5-HT 1A激动剂激活MAP激酶， 在神经元细胞系中抑制半胱天冬酶-3活性和凋亡。我是 定位进入这些领域，并扩大我目前的NIMH支持 将5-HT 1A受体与神经可塑性和抑郁症联系起来的研究。我 我将扩展我的假设，包括神经发生过程中发生的事件， 凋亡第二个主要的职业规划包括获得背景知识， 在人类大脑中执行和分析MRI的经验。Mony DeLeon博士使用 MRI检测内嗅皮层、杏仁核和 在纽约大学医学中心的海马体我的长期目标是利用成像技术 精神病患者人群的纵向研究技术， 怀疑是神经可塑性事件。使用5-HT药物的治疗策略 可以直接测试我的基础研究的临床相关性 调查结果。职业发展计划包括（a）补充培训， （B）探讨5-HT 1A受体在神经发生中的作用 （c）与该领域的国家和国际专家会晤 作为进一步发展治疗策略的一部分， 使用药理学来逆转精神分裂症中发生的神经形态学变化 紊乱